Overview
- Biontech will make $740 million in upfront payments, split equally between Curevac and GlaxoSmithKline.
- The deal imposes a 1 percent royalty on US Covid-19 vaccine revenues dating back to January 1, 2025.
- Curevac grants Biontech and Pfizer a non-exclusive US license for mRNA-based Covid-19 and influenza products, with global rights to follow after the acquisition.
- A significant share of the settlement funds is designated to return to Biontech’s treasury once the takeover closes.
- Both companies confirm the acquisition remains on schedule for year-end completion and insist the settlement is not an admission of liability.